Romain Bouziat

Romain Bouziat

Auto-generated profile, based on publicly available information

Romain Bouziat

Genentech, South San Francisco, 94080, California, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2017 in Science
Verified
Journal Article
Closed access
PDF file
RBRomain Bouziat
Romain Bouziat
RHReinhard Hinterleitner
Reinhard Hinterleitner
JBJudy J. Brown
Judy J. Brown
JSJennifer E. Stencel-Baerenwald
Jennifer E. Stencel-Baerenwald
MIMine Ikizler
Mine Ikizler
BJBana Jabri
Bana Jabri
Viral infections have been proposed to elicit pathological processes leading to the initiation of T helper 1 (TH1) immunity against dietary gluten and celiac disease (CeD). To test this hypothesis and gain insights into mechanisms underlying virus-induced loss of tolerance to dietary antigens, we developed a viral infection model that makes use of two reovirus strains that infect the intestine but differ in their immunopathological outcomes. Reovirus is an avirulent pathogen that elicits protective immunity, but we discovered that it can nonetheless disrupt intestinal immune homeostasis at inductive and effector sites of oral tolerance by suppressing peripheral regulatory T cell (pTreg) conversion and promoting TH1 immunity to dietary antigen. Initiation of TH1 immunity to dietary antigen was dependent on interferon regulatory factor 1 and dissociated from suppression of pTreg conversion, which was mediated by type-1 interferon. Last, our study in humans supports a role for infection with reovirus, a seemingly innocuous virus, in triggering the development of CeD.

17 December 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
SPSamuel B. Pollock
Samuel B. Pollock
CRChristopher M. Rose
Christopher M. Rose
MDMartine Darwish
Martine Darwish
RBRomain Bouziat
Romain Bouziat
LDLélia Delamarre
Lélia Delamarre
JLJennie R. Lill
Jennie R. Lill
Advances in several key technologies, including MHC peptidomics, has helped fuel our understanding of basic immune regulatory mechanisms and identify T cell receptor targets for the development of immunotherapeutics. Isolating and accurately quantifying MHC-bound peptides from cells and tissues enables characterization of dynamic changes in the ligandome due to cellular perturbations. This multi-step analytical process remains challenging, and throughput and reproducibility are paramount for rapidly characterizing multiple conditions in parallel. Here, we describe a robust and quantitative method whereby peptides derived from MHC-I complexes from a variety of cell lines, including challenging adherent lines, can be enriched in a semi-automated fashion on reusable, dry-storage, customized antibody cartridges. TOMAHAQ, a targeted mass spectrometry technique that combines sample multiplexing and high sensitivity, was employed to characterize neoepitopes displayed on MHC-I by tumor cells and to quantitatively assess the influence of neoantigen expression and induced degradation on neoepitope presentation.